બાઇલ ડક્ટ કેન્સર
A two-arm randomized phase III, open-label prospective non-inferiority study ofirinotecan versus oxaliplatin or 5-FU based chemotherapy mFOLFOX or CAPOX forpatients with locally advanced/ metastatic biliary tract cancers BTC previouslytreated with gemcitabine-cisplatin based chemotherapy.
હોસ્પિટલનો સંપર્ક કરો
રજિસ્ટ્રી આ હોસ્પિટલને ટ્રાયલના મુખ્ય સંપર્ક તરીકે બતાવે છે. તેમને પૂછો કે કઈ હોસ્પિટલો દર્દીઓને લઈ રહી છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
A two-arm randomized phase III, open-label prospective non-inferiority study of irinotecan versus oxaliplatin / 5-FU based chemotherapy (mFOLFOX/CAPOX) for patients with locally advanced/ metastatic biliary tract cancers (BTC) previously treated with gemcitabine-cisplatin based chemotherapy. - (BTC-SELECT)
Sponsor: Tata Memorial Hospital
CTRI પર CTRI/2022/01/039568, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 1 Jun 2026 · read by us 5 Nov 2026